Comparative Pharmacology
Head-to-head clinical analysis: DELATESTRYL versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELATESTRYL versus HALOTESTIN.
DELATESTRYL vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone ester; binds to androgen receptors, activating gene transcription and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
50 to 200 mg intramuscularly every 2 to 4 weeks.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
8 days (terminal); requires 5-6 weeks to reach steady state with weekly dosing
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Urinary (90% as glucuronide and sulfate conjugates, 5% as unchanged drug); fecal (5%)
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen
Androgen